Invesco Ltd. Cuts Stock Holdings in AVANOS MEDICAL, INC. $AVNS

Invesco Ltd. trimmed its position in shares of AVANOS MEDICAL, INC. (NYSE:AVNS) by 5.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 345,435 shares of the company’s stock after selling 18,303 shares during the quarter. Invesco Ltd. owned approximately 0.75% of AVANOS MEDICAL worth $4,950,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AVNS. State of Wyoming grew its stake in AVANOS MEDICAL by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after acquiring an additional 2,923 shares during the period. Tower Research Capital LLC TRC grew its stake in AVANOS MEDICAL by 493.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company’s stock valued at $129,000 after acquiring an additional 6,714 shares during the period. EP Wealth Advisors LLC grew its stake in AVANOS MEDICAL by 14.6% in the 4th quarter. EP Wealth Advisors LLC now owns 10,108 shares of the company’s stock valued at $161,000 after acquiring an additional 1,289 shares during the period. Heritage Family Offices LLP acquired a new stake in AVANOS MEDICAL during the 1st quarter worth $146,000. Finally, Mariner LLC boosted its stake in AVANOS MEDICAL by 18.0% during the 4th quarter. Mariner LLC now owns 10,655 shares of the company’s stock worth $170,000 after purchasing an additional 1,625 shares during the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at AVANOS MEDICAL

In other news, Director Gary Blackford acquired 40,000 shares of the firm’s stock in a transaction dated Wednesday, August 13th. The stock was acquired at an average cost of $10.99 per share, with a total value of $439,600.00. Following the completion of the acquisition, the director owned 40,000 shares of the company’s stock, valued at $439,600. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.64% of the company’s stock.

AVANOS MEDICAL Stock Performance

Shares of AVANOS MEDICAL stock opened at $11.89 on Thursday. AVANOS MEDICAL, INC. has a one year low of $9.30 and a one year high of $25.36. The company has a market cap of $551.79 million, a PE ratio of -1.18 and a beta of 1.12. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.58 and a current ratio of 2.64. The business has a 50-day simple moving average of $11.63 and a 200-day simple moving average of $12.92.

AVANOS MEDICAL (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $175.00 million for the quarter, compared to analyst estimates of $165.50 million. AVANOS MEDICAL had a positive return on equity of 6.16% and a negative net margin of 66.89%.During the same period in the prior year, the firm posted $0.34 earnings per share. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. On average, equities research analysts forecast that AVANOS MEDICAL, INC. will post 1.32 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Wall Street Zen cut shares of AVANOS MEDICAL from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Zacks Research raised shares of AVANOS MEDICAL to a “hold” rating in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, the stock presently has an average rating of “Hold”.

AVANOS MEDICAL Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.